Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03172546
Other study ID # 2014_26
Secondary ID 2015-A01596-43
Status Terminated
Phase
First received
Last updated
Start date July 6, 2017
Est. completion date October 15, 2019

Study information

Verified date October 2019
Source University Hospital, Lille
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary objective of the present study is to determine the clinical, biological and genetic determinants of the anticoagulant activity in patients treated with either anti-IIa or anti Xa oral anticoagulants.

The secondary objective is to determine the clinical, biological or genetic determinants of hemorrhagic or thrombotic complications during a one year follow-up.

Results will lead to a better prediction of both drug response and risk of complications.


Description:

Direct oral anticoagulants are changing clinical practices but a better knowledge of factors that may predict both drug response and risk of complications is need.

Anticoagulant activity is influenced by different factors. Because the biological activity is not easy to measure everywhere, it is important to clearly determine factors that are involved.

A cohort of 550 patients that receive either an anti-IIa or an anti-Xa will be recruited.

The primary objective is to determine clinical, biological and genetic determinants of anticoagulant activity.

This objective will be assessed through a multivariate logistic regression (separately for anti-IIa and anti-Xa) with anticoagulant activity as dependent variable.

Variables that will be included in the statistical model are those known or measured at the entry in the cohort such as :

- Clinical factors : age, sex, weight, dosage and time of the last dose

- Biological factors : serum creatinine level, plasma concentration of the drug

- Genetic polymorphisms :

Factor II and CES1 for anti-IIa drugs Factor X, CYP3, CYP3A4, CYP3A5 and ABCG2 for anti-Xa drugs.

By using the same statistical approach and the same variables, predictive factors of either hemorrhagic or thrombotic events will also be evaluated on the whole cohort. The occurence of hemorrhagic and thrombotic complications will then be assessed through a phone call every 3 months during a one-year follow-up.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date October 15, 2019
Est. primary completion date October 15, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient receiving direct oral anticoagulant

- Complete blood count and measure of hemostasis planned

- Patient able to give consent

- Patient with health insurance

Exclusion Criteria:

- Patient not able to consent

- Patient under 18 years old

- Patient refusal

- Patient without health insurance

Study Design


Related Conditions & MeSH terms


Intervention

Genetic:
PK-PD genetic polymorphisms
PK-PD genetic polymorphisms analysis in patients receiving either anti-IIa or anti-Xa treatment

Locations

Country Name City State
France University Hospital Lille

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Lille

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of anticoagulant activity level Multivariate analysis to determine clinical, biological or genetic predictors of anticoagulant activity level as measured by anti-IIa or anti-Xa activity Baseline
Secondary Occurence of any hemorrhagic complication Multivariate analysis to determine clinical, biological or genetic predictors of hemorrhagic complications under direct oral anticoagulant One year follow-up
Secondary Occurence of any thrombotic complication Multivariate analysis to determine clinical, biological or genetic predictors of thrombotic complications under direct oral anticoagulant One year follow-up
See also
  Status Clinical Trial Phase
Recruiting NCT04010955 - Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON)
Recruiting NCT04673695 - A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 Phase 1
Completed NCT03893591 - A Prospective Study to Examine the Need to Adjust the Dose of Apixaban When Used in Atrial Fibrillation and Obesity
Completed NCT03895502 - Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study Phase 4
Completed NCT03154489 - Effectiveness of a Multidisciplinary Medication Review With Follow-up for Patients Treated With Coumarin Anticoagulants in Primary Care N/A
Completed NCT04305821 - Medico-economic Interest of the Protein S100b in Mild Head Trauma Under Anti-thrombotics
Recruiting NCT06020560 - Study of Low Molecular Weight Heparins Phase 4
Not yet recruiting NCT05788900 - Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Intravenous Administration Phase 1
Not yet recruiting NCT05788913 - Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Subcutaneous Administration Phase 1
Not yet recruiting NCT04592822 - A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition Phase 1
Recruiting NCT03772457 - Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban
Completed NCT03323320 - Evaluation of Patient's Knowledge of Their NACO Treatment N/A
Recruiting NCT04257487 - Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study) Phase 3
Completed NCT04272723 - Management of Venous Thromboembolism in France: a National Survey Among Vascular Medicine Physicians
Recruiting NCT04867200 - A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Volunteers Phase 1